Moderna | Sustainability Performance
A biotechnology company focused on developing mRNA-based vaccines and therapeutics for a wide range of diseases, including infectious diseases, cancer, and rare genetic disorders.
2010
United States
1,001 - 5,000 employees
Biotechnology
$1B - 10B in revenue
N/A in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#6864
Overallⓘ#1468
in United Statesⓘ#153
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsDigital emissionsEnergy consumptionWaste ManagementWater ManagementNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Laggard
Leading
Laggard
Critical
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Water consumption intensity (m³ /$M)
Industry Benchmark
15.9
B/M 10.8
383.4
B/M 128.6
71.9
B/M 27.9
106.9
B/M 102.0
Powered by illuminem and GIST Impact
Controversy level
- Moderna's mRNA COVID vaccine was linked to rare myocarditis cases, particularly in young males.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
4-6
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.